149 related articles for article (PubMed ID: 10599548)
1. The pharmacological profile of a novel norpregnance progestin (trimegestone).
Philibert D; Bouchoux F; Degryse M; Lecaque D; Petit F; Gaillard M
Gynecol Endocrinol; 1999 Oct; 13(5):316-26. PubMed ID: 10599548
[TBL] [Abstract][Full Text] [Related]
2. In vitro characterization of trimegestone: a new potent and selective progestin.
Zhang Z; Lundeen SG; Zhu Y; Carver JM; Winneker RC
Steroids; 2000; 65(10-11):637-43. PubMed ID: 11108870
[TBL] [Abstract][Full Text] [Related]
3. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.
Fuhrmann U; Krattenmacher R; Slater EP; Fritzemeier KH
Contraception; 1996 Oct; 54(4):243-51. PubMed ID: 8922878
[TBL] [Abstract][Full Text] [Related]
4. The preclinical biology of a new potent and selective progestin: trimegestone.
Winneker RC; Bitran D; Zhang Z
Steroids; 2003 Nov; 68(10-13):915-20. PubMed ID: 14667983
[TBL] [Abstract][Full Text] [Related]
5. Nestorone: a progestin with a unique pharmacological profile.
Kumar N; Koide SS; Tsong Y; Sundaram K
Steroids; 2000; 65(10-11):629-36. PubMed ID: 11108869
[TBL] [Abstract][Full Text] [Related]
6. Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone.
Lundeen SG; Zhang Z; Zhu Y; Carver JM; Winneker RC
J Steroid Biochem Mol Biol; 2001 Aug; 78(2):137-43. PubMed ID: 11566438
[TBL] [Abstract][Full Text] [Related]
7. Effects of 17 beta-estradiol and trimegestone alone, and in combination, on the bone and uterus of ovariectomized rats.
Lepescheux L; Secchi J; Gaillard-Kelly M; Miller P
Gynecol Endocrinol; 2001 Aug; 15(4):312-20. PubMed ID: 11560106
[TBL] [Abstract][Full Text] [Related]
8. Effect of trimegestone alone or in combination with estradiol on bone mass and bone turnover in an adult rat model of osteopenia.
Bouali Y; Gaillard-Kelly M; Marie PJ
Gynecol Endocrinol; 2001 Feb; 15(1):48-55. PubMed ID: 11293924
[TBL] [Abstract][Full Text] [Related]
9. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.
Muhn P; Fuhrmann U; Fritzemeier KH; Krattenmacher R; Schillinger E
Ann N Y Acad Sci; 1995 Jun; 761():311-35. PubMed ID: 7625729
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays.
Fuhrmann U; Slater EP; Fritzemeier KH
Contraception; 1995 Jan; 51(1):45-52. PubMed ID: 7750284
[TBL] [Abstract][Full Text] [Related]
11. Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives.
Schoonen WG; Deckers GH; de Gooijer ME; de Ries R; Kloosterboer HJ
J Steroid Biochem Mol Biol; 2000 Nov; 74(4):213-22. PubMed ID: 11162927
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical properties of trimegestone: a potent and selective progestin.
Sitruk-Ware R; Bossemeyer R; Bouchard P
Gynecol Endocrinol; 2007 Jun; 23(6):310-9. PubMed ID: 17616854
[TBL] [Abstract][Full Text] [Related]
13. Progesterone-Progestin receptors.
Raynaud JP; Philibert D; Azadian-Boulanger G
Basic Life Sci; 1974; 4(PART A):143-60. PubMed ID: 4374925
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of chlormadinone acetate and its 3alpha- and 3beta-hydroxy metabolites on progesterone, androgen and glucocorticoid receptors.
Schneider J; Kneip C; Jahnel U
Pharmacology; 2009; 84(2):74-81. PubMed ID: 19590256
[TBL] [Abstract][Full Text] [Related]
15. Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids.
Poulin R; Baker D; Poirier D; Labrie F
Breast Cancer Res Treat; 1991; 17(3):197-210. PubMed ID: 1645605
[TBL] [Abstract][Full Text] [Related]
16. Binding of a contraceptive progestogen ORG 2969 and its metabolites to receptor proteins and human sex hormone binding globulin.
Bergink EW; Hamburger AD; de Jager E; van der Vies J
J Steroid Biochem; 1981 Feb; 14(2):175-83. PubMed ID: 6451769
[TBL] [Abstract][Full Text] [Related]
17. [An introduction to synthetic progestogens pharmacology (author's transl)].
Raynaud JP; Bercovici JP
Ann Endocrinol (Paris); 1979; 40(3 Suppl):300-20. PubMed ID: 386914
[TBL] [Abstract][Full Text] [Related]
18. Estrogenic and progestational activity of 7alpha-methyl-19-nortestosterone, a synthetic androgen.
Beri R; Kumar N; Savage T; Benalcazar L; Sundaram K
J Steroid Biochem Mol Biol; 1998 Nov; 67(3):275-83. PubMed ID: 9879986
[TBL] [Abstract][Full Text] [Related]
19. Trimegestone: expanding therapeutic choices for the treatment of the menopause.
Wahab M; Al-Azzawi F
Expert Opin Investig Drugs; 2001 Sep; 10(9):1737-44. PubMed ID: 11772282
[TBL] [Abstract][Full Text] [Related]
20. Endometrial effects of three doses of trimegestone, a new orally active progestogen, on the postmenopausal endometrium.
Ross D; Godfree V; Cooper A; Pryse-Davies J; Whitehead MI
Maturitas; 1997 Sep; 28(1):83-8. PubMed ID: 9391999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
